Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Based on the results from preclinical study, the investigators suggest that the addition of
simvastatin at a dose of cardiovascular use (40 ~ 80 mg qd daily) may overcome cetuximab
resistance in KRAS mutant colorectal cancer via B-Raf protein degradation and inducing Bim
and Bad. Given the result of a phase II FOLFIRI plus cardiovascular dose of simvastatin (80mg
qd daily) and this study, phase II study of conventional cetuximab treatment with 40 mg
simvastatin is planned in metastatic colorectal cancer patients with KRAS mutation.